# US 2021/0079063 A1 · Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079063 A1
- Document ID: US20210079063A1
- Status: Published application
- Kind: A1
- Application number: 15/733,530
- Filed: 2019-02-21
- Published: 2021-03-18
- Earliest claimed: 2018-02-23
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Shohei KOIDE; Shun-Ichi TANAKA; Akiko KOIDE
- Web page: https://patentgrep.com/patent/US20210079063A1

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C40B 40/10: Libraries containing peptides or polypeptides, or derivatives thereof
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The current application describes various compositions and methods for the production of FN3-based binding proteins with improved stability properties. Aspects of the disclosure relate to polypeptides comprising a variant fibronectin type III (FN3) domain from Sulfolobus tokodaii or Pyrococcus horikoshii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.

## Claims

### Claim 1

A polypeptide comprising a variant fibronectin type III (FN3) domain from Sulfolobus tokodaii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the non-variant FN3 domain comprises at least 70% identity to SEQ ID NO:1.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein the non-variant FN3 domain comprises SEQ ID NO:1.

### Claim 4 (depends on 1)

The polypeptide of claim 1, wherein the non-variant FN3 domain comprises a polypeptide with at least 70% identity to SEQ ID NO:2 (STOFN3-2), 3 (STOFN3-3), or 4 (STOFN3-4).

### Claim 5 (depends on 1)

The polypeptide of claim 1, wherein the non-variant FN3 domain comprises SEQ ID NO:2, 3, or 4.

### Claim 6 (depends on 1, 2, 3, 4)

The polypeptide of any one of claims 1-4, wherein the amino acid substitution comprises one or more substitutions of the FN3 domain corresponding to amino acid positions 1, 2, and 3 of SEQ ID NO:1.

### Claim 7 (depends on 6)

The polypeptide of claim 6, wherein the amino acid substitutions at one or more positions corresponding to amino acid positions 1, 2, and/or 3 of SEQ ID NO:1 are a substitution with a hydrophilic amino acid or combinations thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The polypeptide of any one of claims 1-7, wherein the amino acid insertion comprises one or more amino acid insertions of the FN3 domain after the amino acid corresponding to amino acid position 84 of SEQ ID NO:1.

### Claim 9 (depends on 8)

The polypeptide of claim 8, wherein the amino acid insertion comprises 1-3 amino acids.

### Claim 10 (depends on 9)

The polypeptide of claim 9, wherein the inserted amino acids are proline and serine or combinations thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The polypeptide of any one of claims 1-10, wherein the substitution comprises one or more substitutions of the FN3 domain corresponding to amino acid positions 4, 14, 28, and 58 of SEQ ID NO:1.

### Claim 12 (depends on 11)

The polypeptide of claim 11, wherein the substitution corresponding to amino acid position 4 of SEQ ID NO:1 is with a valine.

### Claim 13 (depends on 11, 12)

The polypeptide of claim 11 or 12, wherein the substitution corresponding to amino acid position 14 of SEQ ID NO:1 is with a proline.

### Claim 14 (depends on 11, 12, 13)

The polypeptide of any one of claims 11-13, wherein the substitution corresponding to amino acid position 28 of SEQ ID NO:1 is with a tyrosine.

### Claim 15 (depends on 11, 12, 13, 14)

The polypeptide of any one of claims 11-14, wherein the substitution corresponding to amino acid position 58 of SEQ ID NO:1 is with a proline.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The polypeptide of any one of claims 1-15, wherein the one or more amino acid substitutions or insertions in the non-loop segment is in one or more of beta strand C or beta strand D.

### Claim 17 (depends on 16)

The polypeptide of claim 16, wherein the one or more amino acid substitutions or insertions correspond to or after positions 28, 29, 30, 31, 32, 33, 34, or 35 of SEQ ID NO:1.

### Claim 18 (depends on 16)

The polypeptide of claim 16, wherein the one or more amino acid substitutions or insertions correspond to or after positions 38, 39, 40, 41, 42, 43, 44, 45, or 46 of SEQ ID NO:1.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The polypeptide of any one of claims 1-18, wherein the one or more amino acid substitutions or insertions in the loop region of FN3 are in the BC loop, DE loop, FG loop and/or CD loop.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The polypeptide of any one of claims 1-19, wherein the DE loop does not comprise any inserted amino acids.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The polypeptide of any one of claims 1-20, wherein the EF loop comprises less than 3 substitutions or insertions.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The polypeptide of any one of claims 1-21, wherein the FN3 domain does not have substitutions at amino acid positions corresponding to positions 69 and 77 of SEQ ID NO:1.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The polypeptide of any one of claims 1-22, further comprising a non-FN3 polypeptide that enhances the FN3 polypeptide binding affinity for a target molecule.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The polypeptide of any one of claims 1-23, comprising or further comprising an insertion or deletion of at least 1 amino acids in at least one loop region of FN3.

### Claim 25 (depends on 24)

The polypeptide of claim 24, wherein at least one loop region of FN3 comprises an insertion of at least 2 amino acids.

### Claim 26 (depends on 25)

The polypeptide of claim 25, wherein at least one region of FN3 comprises an insertion of 2 to 25 amino acids in at least one loop region.

### Claim 27 (depends on 24)

The polypeptide of claim 24, wherein at least two loop regions comprise an insertion.

### Claim 28 (depends on 24)

The polypeptide of claim 24, wherein at least one loop region of FN3 comprises a deletion of at least 1 amino acid.

### Claim 29 (depends on 28)

The polypeptide of claim 28, wherein at least one loop region of FN3 comprises a deletion of 2 to 10 amino acids.

### Claim 30 (depends on 28)

The polypeptide of claim 28, wherein at least two loop regions comprise a deletion of at least 1 amino acid.

### Claim 31 (depends on 24)

The polypeptide of claim 24, wherein the polypeptide comprises at least 1 amino acid insertion and 1 amino acid deletion in at least one loop region.

### Claim 32 (depends on 31)

The polypeptide of claim 31, wherein the polypeptide comprises an insertion and deletion of at least 1 amino acid in the same loop region.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The polypeptide of any one of claims 1-32, wherein the polypeptide further comprises one or more serine residues immediately before amino acid 1 or immediately after amino acid 84 of SEQ ID NO:1.

### Claim 34

A polypeptide comprising a variant fibronectin type III (FN3) domain from Pyrococcus horikoshii comprising one or more amino acid substitutions or insertions in a loop region of FN3, in a non-loop region of FN3, or in both.

### Claim 35 (depends on 34)

The polypeptide of claim 34, wherein the non-variant FN3 domain comprises at least 70% identity to SEQ ID NO:6

### Claim 36 (depends on 35)

The polypeptide of claim 35, wherein the non-variant FN3 domain comprises SEQ ID NO:6.

### Claim 37 (depends on 34, 35, 36)

The polypeptide of any one of claims 34-36, wherein the one or more amino acid substitutions or insertions in the non-loop segment is in one or more of beta strand C or beta strand D.

### Claim 38 (depends on 37)

The polypeptide of claim 37, wherein the one or more amino acid substitutions or insertions correspond to or after positions 13 and/or 14 of SEQ ID NO:6.

### Claim 39 (depends on 37, 38)

The polypeptide of claim 37 or 38, wherein the one or more amino acid substitutions or insertions correspond to or after positions 20, 21, 22, 23, 24, 25, 26, and/or 27 of SEQ ID NO:6.

### Claim 40 (depends on 37, 38, 39)

The polypeptide of any one of claims 37-39, wherein the one or more amino acid substitutions or insertions correspond to or after positions 36 and/or 37 of SEQ ID NO:6.

### Claim 41 (depends on 37, 38, 39, 40)

The polypeptide of any one of claims 37-40, wherein the one or more amino acid substitutions or insertions correspond to or after positions 40, 41, 42, 43, 44, 45, 46, 47, and/or 48 of SEQ ID NO:6.

### Claim 42 (depends on 37, 38, 39, 40, 41)

The polypeptide of any one of claims 37-41, wherein the one or more amino acid substitutions or insertions correspond to or after positions 54, 55, 56, 57, 58, and/or 59 of SEQ ID NO:6.

### Claim 43 (depends on 37, 38, 39, 40, 41, 42)

The polypeptide of any one of claims 37-42, wherein the one or more amino acid substitutions or insertions correspond to or after positions 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, and/or 74 of SEQ ID NO:6.

### Claim 44 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The polypeptide of any one of claims 34-43, wherein the one or more amino acid substitutions or insertions in the loop region of FN3 are in the AB loop, BC loop, CD loop, DE loop, EF loop, and/or FG loop.

### Claim 45 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The polypeptide of any one of claims 34-44, further comprising a non-FN3 polypeptide that enhances the FN3 polypeptide binding affinity for a target molecule.

### Claim 46 (depends on 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The polypeptide of any one of claims 34-45, comprising or further comprising an insertion or deletion of at least 1 amino acids in at least one loop region of FN3.

### Claim 47 (depends on 46)

The polypeptide of claim 46, wherein at least one loop region of FN3 comprises an insertion of at least 2 amino acids.

### Claim 48 (depends on 47)

The polypeptide of claim 47, wherein at least one region of FN3 comprises an insertion of 2 to 25 amino acids in at least one loop region.

### Claim 49 (depends on 46)

The polypeptide of claim 46, wherein at least two loop regions comprise an insertion.

### Claim 50 (depends on 46)

The polypeptide of claim 46, wherein at least one loop region of FN3 comprises a deletion of at least 1 amino acid.

### Claim 51 (depends on 50)

The polypeptide of claim 50, wherein at least one loop region of FN3 comprises a deletion of 2 to 10 amino acids.

### Claim 52 (depends on 50)

The polypeptide of claim 50, wherein at least two loop regions comprise a deletion of at least 1 amino acid.

### Claim 53 (depends on 46)

The polypeptide of claim 46, wherein the polypeptide comprises at least 1 amino acid insertion and 1 amino acid deletion in at least one loop region.

### Claim 54 (depends on 53)

The polypeptide of claim 53, wherein the polypeptide comprises an insertion and deletion of at least 1 amino acid in the same loop region.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The polypeptide of any one of claims 1-54, wherein the polypeptide is isolated.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The polypeptide of any one of claims 1-55, wherein the polypeptide is recombinant.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The polypeptide of any one of claims 1-56, wherein the polypeptide is synthetic.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The polypeptide of any one of claims 1-57, wherein the polypeptide binds specifically to a target motif.

### Claim 59 (depends on 58)

The polypeptide of claim 58, wherein the polypeptide further comprises a polypeptide comprising a biorecognition module including a molecular recognition domain; wherein the polypeptide comprising the biorecognition molecule and the polypeptide comprising the variant FN3 domain are operatively linked together either directly or indirectly via the linker, and are spatially oriented to bind on the same, overlapping, or distinct sites within the target motif.

### Claim 60 (depends on 59)

The polypeptide of claim 59, wherein the Kd for the polypeptide being equal to or lower than one μM.

### Claim 61 (depends on 59, 60)

The polypeptide of claim 59 or 60, wherein the target motif is a peptide, a phosphorylated peptide or a methylated peptide.

### Claim 62 (depends on 59, 60, 61)

The polypeptide of any of claims 59-61, wherein the target motif is present within a protein.

### Claim 63 (depends on 59, 60, 61, 62)

The polypeptide of any of claims 59-62, wherein the molecular recognition domain comprises an interaction domain or mutants of interaction domains.

### Claim 64 (depends on 63)

The polypeptide of claim 63, wherein the interaction domain is selected from the group consisting of PDZ, WW, SH2, PTB, SH3, Bromo, Chromo, PHD, Polo-box and FHA domains.

### Claim 65 (depends on 59, 60, 61, 62, 63, 64)

The polypeptide of any of claims 59-64, wherein the polypeptide comprising the variant FN3 domain further comprises a first signaling moiety and the polypeptide comprising the biorecognition molecule further comprises a second signaling moiety and wherein the first and second signaling moieties are capable of interacting to produce a detectable signal.

### Claim 66 (depends on 65)

The polypeptide of claim 65, wherein the signaling moiety is a dye, a quencher, a reporter protein, or a quantum dot.

### Claim 67 (depends on 65)

The polypeptide of claim 65, wherein the first and second signaling moieties comprise a fluorescent resonance energy transfer (FRET) donor group and a FRET acceptor group, respectively, and binding of the first and second molecular recognition domains to the target motif results in a change in the FRET efficiency between the FRET donor and FRET acceptor groups.

### Claim 68

A polypeptide library comprising a plurality of modified FN3 domain polypeptides comprising one or more amino acid substitutions, insertions, or deletions a loop region of FN3, in a non-loop region of FN3, or in both; wherein the unmodified FN3 domain comprises a polypeptide comprising the amino acid sequence of SEQ ID NOS:1-4 or 6.

### Claim 69 (depends on 68)

The polypeptide library of claim 68, wherein the FN3 domain polypeptides comprises one or more amino acid substitutions corresponding to amino acid positions corresponding to positions 1, 2, 3, 4, 14, 28, and/or 58 of SEQ ID NO:1.

### Claim 70 (depends on 68, 69)

The polypeptide library of claim 68 or 69, wherein the FN3 domain polypeptides further comprise one or more amino acid substitutions corresponding to amino acid positions 13, 14, 15, 16, 22, 23, 24, 25, 26, 27, 36, 37, 47, 48, 49, 54, 55, 56, 57, 58, 59, 60, 71, 72, 73, 74, 75, 76, 77, 78, 79 and/or 80 of SEQ ID NO:1.

### Claim 71 (depends on 68)

The polypeptide library of claim 68, wherein the FN3 domain polypeptides further comprise one or more amino acid substitutions corresponding to amino acid positions of SEQ ID NO:6.

### Claim 72 (depends on 68, 69, 70, 71)

The polypeptide library of any one of claims 68-71, wherein the FN3 domain polypeptides are at least 50%, 60%, 70%, 80%, or 90% identical to SEQ ID NO:1, 2, 3, 4, or 6.

### Claim 73 (depends on 68, 69, 70, 71, 72)

The polypeptide library of any one of claims 68-72, further comprising a non-FN3 polypeptide that enhances the FN3 polypeptide binding affinity for a target molecule.

### Claim 74 (depends on 68, 69, 70, 71, 72, 73)

The polypeptide library of any one of claims 68-73, comprising or further comprising an insertion or deletion of at least 1 amino acids in at least one loop region of the FN3 domain polypeptides.

### Claim 75 (depends on 74)

The polypeptide library of claim 74, wherein at least one loop region of FN3 comprises an insertion of at least 2 amino acids.

### Claim 76 (depends on 75)

The polypeptide library of claim 75, wherein at least one region of FN3 comprises an insertion of 2 to 25 amino acids in at least one loop region.

### Claim 77 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76)

The polypeptide library of any one of claims 68-76, wherein at least two loop regions comprise an insertion.

### Claim 78 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The polypeptide library of any one of claims 68-77, wherein at least one loop region of FN3 comprises a deletion of at least 1 amino acid.

### Claim 79 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The polypeptide library of any one of claims 68-78, wherein at least one loop region of FN3 comprises a deletion of 2 to 10 amino acids.

### Claim 80 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The polypeptide library of any one of claims 68-79, wherein at least two loop regions comprise a deletion of at least 1 amino acid.

### Claim 81 (depends on 74)

The polypeptide library of claim 74, wherein the polypeptide comprises at least 1 amino acid insertion and 1 amino acid deletion in at least one loop region.

### Claim 82 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The polypeptide library of any one of claims claim 68-81, wherein the FN3 domain polypeptides comprise an insertion and deletion of at least 1 amino acid in the same loop region.

### Claim 83 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The polypeptide library of any one of claims 68-82, wherein the library is pre-selected to bind a target.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A polynucleotide encoding the polypeptide of claims 1-67.

### Claim 85 (depends on 84)

The polynucleotide of claim 84, wherein the polynucleotide is an expression construct.

### Claim 86 (depends on 85)

The polynucleotide of claim 85, wherein the expression construct is capable of expressing the encoded polypeptide in a bacteria.

### Claim 87 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

A polynucleotide composition encoding the polypeptide library of any one of claims 68-83.

### Claim 88

A monobody library comprising a plurality of polypeptides having a variant fibronectin type III (FN3) domain, compared to wildtype (SEQ ID NOS:1-4 or 6), comprising one or more alterations in a beta strand or a loop region.

### Claim 89 (depends on 88)

The monobody of claim 88, wherein the alterations are in one or more of beta strand C, beta strand D, BC loop, CD loop, DE loop, or and/or FG loop.

### Claim 90 (depends on 88, 89)

The monobody of claim 88 or 89, wherein the monobody comprises one or more of the variant amino acids corresponding to position 1, 2, 3, 4, 14, 28, and/or 58 of SEQ ID NO:1.

### Claim 91 (depends on 88, 90)

The monobody library of claim 88 or 90, wherein the variant FN3 domains further comprise an insertion, substitution, or deletion of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 amino acids in at least one loop region of FN3.

### Claim 92 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

A method for selecting a protein binding domain specific for a target comprising:
(a) detecting target specific binding of one or more members of a polypeptide library of any one of claims 68-83; and
(b) selecting the protein binding domain that specifically binds the target.

### Claim 93 (depends on 92)

The method of claim 92, further comprising first preparing the polypeptide library.

### Claim 94 (depends on 92)

The method of claim 92, further comprising isolating the selected protein binding domain that specifically binds the target.

### Claim 95 (depends on 94)

The method of claim 94, further comprising determining the amino acid of sequence of the selected protein binding domain.

### Claim 96 (depends on 95)

The method of claim 95, further comprising generating the selected protein binding domain after the amino acid sequence has been determined.

### Claim 97 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

A method of identifying a polypeptide that specifically binds a target comprising detecting specific binding of one or more polypeptides of a polypeptide library of any one of claims 68-83.

### Claim 98

A method of detecting a target molecule comprising contacting a sample containing the target with a fibronectin type III (FN3) binding domain that specifically binds the target.

### Claim 99 (depends on 97)

A method of producing a fibronectin type III (FN3) variant comprising:
(a) expressing a polypeptide comprising a amino acid sequence selected in claim 97; and
(b) isolating and/or purifying the expressed variant FN3 domain from a host cell expressing the variant FN3.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A kit comprising a plurality of polypeptides as described in any one of claims 1-67.

### Claim 101 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

A kit comprising a polypeptide library as described in any one of claims 68-83.

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A kit comprising a plurality of polynucleotides encoding FN3 domain variants described in claims 1-57. non-variant FN3 domain comprises SEQ ID NO:1.

### Claim 103 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

A method of making a polypeptide or polypeptide library according to any one of claims 1-83 comprising expressing the polynucleotide of any of claims 84-87 in a host cell.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A method of testing a polypeptide according to any one of claims 1-67, the method comprising contacting the polypeptide with a target molecule and testing for binding activity between the polypeptide and the target molecule.
